Comparison Overview

Inspire Pharma

VS

UCB

Inspire Pharma

4 El Tahrir St, Sheraton Heliopolis sheraton heliopolis Cairo, EG
Last Update: 2025-03-14 (UTC)
View Profile
Between 800 and 849
http://www.inspirepharma.com

Inspire pharma is a national Egyptian pharmaceutical company established in 2005, founded by a determined group of partners to be a unique business model in the healthcare industry in Egypt. After a three-year ride in legislative and licensing processes, we were successful in acquiring distinguished talents at several levels to drive and deliver organizational KPIs. Together with 100 molecules cued up in the pipeline 15 molecules were launched successfully since 2010 . Our management team is not only emphasizing the financial objectives, but rather, it’s equally determined to establish a unique business culture and inspiring code of conduct through our core values.

NAICS: 325
NAICS Definition:
Employees: 201-500
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

UCB

Allée de la Recherche, 60, Brussels, undefined, undefined, BE
Last Update: 2025-03-04 (UTC)
Between 800 and 849
http://www.ucb.com

UCB – Inspired by patients. Driven by science. At UCB, we put our heart, soul and skills into making a difference for people living with severe diseases. We look to transform patients’ lives by pushing the boundaries of what is possible. With us, our talents makes the most of who they are, unlocking innovation and setting new standards for patients. Everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” And to find the answers, we connect globally with patients and their families living with the physical and social burdens of severe disease. These connections give us new perspectives, drive our innovation, and offer a hope for a new generation of therapies that will help to transform lives. UCB – The Facts With more than 9000 employees in around 40 countries, we are a global biopharmaceutical company headquartered in Brussels, Belgium which invests more than 25% of revenue in cutting-edge scientific research to meet unmet patient needs. A few other reasons that make UCB an amazing place to work: - Promising pipeline that includes several novel molecules; - 2024 Key Financials: € 6.15 billion global revenue Specialties: Neurology, Immunology

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 13,480
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/inspire-pharma.jpeg
Inspire Pharma
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/ucb-pharma.jpeg
UCB
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Inspire Pharma
100%
Compliance Rate
0/4 Standards Verified
UCB
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Inspire Pharma in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for UCB in 2025.

Incident History — Inspire Pharma (X = Date, Y = Severity)

Inspire Pharma cyber incidents detection timeline including parent company and subsidiaries

Incident History — UCB (X = Date, Y = Severity)

UCB cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/inspire-pharma.jpeg
Inspire Pharma
Incidents

No Incident

https://images.rankiteo.com/companyimages/ucb-pharma.jpeg
UCB
Incidents

No Incident

FAQ

Inspire Pharma company demonstrates a stronger AI Cybersecurity Score compared to UCB company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, UCB company has disclosed a higher number of cyber incidents compared to Inspire Pharma company.

In the current year, UCB company and Inspire Pharma company have not reported any cyber incidents.

Neither UCB company nor Inspire Pharma company has reported experiencing a ransomware attack publicly.

Neither UCB company nor Inspire Pharma company has reported experiencing a data breach publicly.

Neither UCB company nor Inspire Pharma company has reported experiencing targeted cyberattacks publicly.

Neither Inspire Pharma company nor UCB company has reported experiencing or disclosing vulnerabilities publicly.

Neither Inspire Pharma nor UCB holds any compliance certifications.

Neither company holds any compliance certifications.

Neither Inspire Pharma company nor UCB company has publicly disclosed detailed information about the number of their subsidiaries.

UCB company employs more people globally than Inspire Pharma company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Inspire Pharma nor UCB holds SOC 2 Type 1 certification.

Neither Inspire Pharma nor UCB holds SOC 2 Type 2 certification.

Neither Inspire Pharma nor UCB holds ISO 27001 certification.

Neither Inspire Pharma nor UCB holds PCI DSS certification.

Neither Inspire Pharma nor UCB holds HIPAA certification.

Neither Inspire Pharma nor UCB holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

The Bold Page Builder plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the ‘percentage’ parameter in all versions up to, and including, 5.4.5 due to insufficient input sanitization and output escaping. This makes it possible for authenticated attackers, with Contributor-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 6.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N
References
Description

The ComboServlet in Liferay Portal 7.4.0 through 7.4.3.111, and older unsupported versions, and Liferay DXP 2023.Q4.0 through 2023.Q4.2, 2023.Q3.1 through 2023.Q3.5, 7.4 GA through update 92, 7.3 GA through update 35, and older unsupported versions does not limit the number or size of the files it will combine, which allows remote attackers to create very large responses that lead to a denial of service attack via the URL query string.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary directories on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and create arbitrary directories on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary files on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 7.5
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:H
cvss4
Base: 8.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:H/SC:N/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References